Driving precision oncology forward

We provide specialized oncology testing backed by deep scientific experience and advanced technologies, enabling faster clinical progress and reliable data for precision medicine.

scientist-in-lab
Custom oncology assay development

We design, optimize, and validate oncology‑specific assays across PCR, ddPCR, flow cytometry, Sanger/NGS platforms, NanoString, and more – tailored to your therapeutic, Context of Use (COU) and biomarker strategy.

detailed-view-of-a-computer-interface-used-by-geneticists-showing-a-complex-genome-mapping-software-with-colorful-dna-strands-without-displaying-any-personal-identity-in-a-modern-research
Advanced genomic & molecular profiling

From targeted NGS panels to whole exome and RNA sequencing, our molecular assays support tumor profiling and the identification of known and emerging biomarkers.

pancancer-iq
PanCancerIQ™ comprehensive genomic profiling

Our PanCancerIQ NGS assay analyzes 523 genes to detect mutations, indels, CNVs, and gene fusions from RNA. This comprehensive panel also reports MSI (microsatellite instability) and TMB (tumor mutation burden), delivering broad tumor insights with less tissue and greater efficiency than serial biomarker tests. Validated for tissue and liquid biopsies (cfDNA).

cytokine
Immuno‑oncology expertise

With over 35 years supporting complex immune‑response studies, we offer assays for CAR‑T therapy monitoring, immune activation, cytokine analysis, and tumor‑immune interactions.

cancer-tumor-cells
Predictive & pharmacodynamic biomarkers

We support biomarker‑driven oncology programs with assays that assess treatment response, resistance pathways, tumor mutational burden, and immune signatures.

dna-double-helix-model-for-genetic-research-molecular-structures-in-biotechnology-laboratory-insights-into-chromosomes-and-gene-editing-techniques
Cell & gene therapy support

We provide specialized assays and advanced technologies, including flow cytometry, NanoString, qPCR/ddPCR, and immune monitoring to evaluate safety, efficacy, biodistribution, and immune response in cutting‑edge cell and gene therapy programs tied to oncology development.

Expertise that elevates every study

With unmatched customization, integrated genomics, and specialized immuno‑oncology capabilities, we deliver clarity in even the most complex cancer research.

scientist-man-thinking-or-test-tubes-in-laboratory-pharma

We tailor assays to your study for optimal sensitivity, specificity, and platform fit.

Learn More Arrow Right Icon
glowing-blue-dna-strand-showcasing-the-intricate-double-helix-structure-illuminated-in-a-molecular-visualization-environment_1583788132

Integrated NGS, PCR/ddPCR, and bioinformatics deliver faster, seamless multi‑omic insights.

Learn More Arrow Right Icon
specific-cytokine-receptors-on-the-target-cell-surface

Unmatched immune‑oncology depth across flow cytometry, cytokine panels, and CAR‑T assays.

Learn More Arrow Right Icon
confident-scientist

Proven in advancing oncology breakthroughs, including early oncolytic viral therapies.

Learn More Arrow Right Icon

Advancing oncology with confidence

Where scientific rigor meets responsive service – ensuring your milestones stay on track.

biomarkers-1
End‑to‑end translational support

Our integrated oncology solutions span early discovery, translational research, and clinical trial testing – helping sponsors move from biomarker hypothesis to validated clinical endpoints faster.

bioinformatics-capabilities
Industry‑leading innovation in precision medicine

We combine next‑generation sequencing, advanced bioinformatics, and custom assay design to deliver meaningful genomic insights for patient selection, trial stratification, and therapeutic decision‑making.

precision-oncology_adobestock_1779184321
Expertise in complex modalities

From cell & gene therapies to oncolytic vectors and immunotherapies, our scientists bring experience supporting some of the industry’s most challenging oncology platforms.

nanostrings
Flexible, scalable testing built around you

With broad platform coverage and a customizable service model, we adapt to the unique needs of emerging biotech and global pharma alike – accelerating timelines without sacrificing quality.

eurofins-lenexa-05

Powering oncology biomarker insights

Successful oncology development depends on biomarker insights that help characterize disease, evaluate treatment response, and identify the right patients. Our oncology-focused platforms support biomarker strategies across the clinical development lifecycle, generating high-quality data to advance immuno-oncology, targeted therapies, and cell and gene therapy programs.

  • ELISA and ligand binding assays performed on platforms including Gyrolab®, MSD® QuickPlex SQ 120 and S 600, SpectraMax®, EnVision™, and EnSight™ for sensitive protein biomarker quantification.

  • Flow cytometry using BD FACSymphony™, BD FACSCanto™ II, BD Lyric™, and NovoCyte Quanteon™ for comprehensive immune cell phenotyping and characterization.

  • Molecular testing and genomic analysis through Illumina MiSeq™, NextSeq™, and NovaSeq™, QuantStudio™ 5 and 7 Pro, Bio-Rad QX200 ddPCR, and ABI 3730XL Sanger Sequencing platforms.

  • Cell-based functional assays including ELISpot on the CTL ImmunoSpot® S3 platform to assess cellular immune responses and mechanism of action.

  • Multiplex biomarker analysis utilizing Luminex® 100, 200, and MAGPIX® systems for efficient profiling of multiple analytes from limited sample volumes. 

  • Digital cell imaging and quantification with the Revvity Celigo® platform to support cell therapy and oncology research applications.

Together, these platforms enable the assessment of immune responses, tumor-associated biomarkers, genomic alterations, and pharmacodynamic endpoints - helping sponsors make informed decisions and accelerate oncology development with confidence.